452 Combination treatment using KISIMATM protein-based cancer vaccine and systemic STING agonist results in profound modulation of tumor microenvironment and improved tumor control

• Matteo Rossi,
• Elodie Belnoue,
• Susanna Carboni,
• Wilma Besson-Di Berardino,
• Erika Riva,
• Marie-Laure Santiago-Raber,
• Madiha Derouazi

Affiliations

Matteo Rossi

AMAL Therapeutics, Geneva, Switzerland

Elodie Belnoue

AMAL Therapeutics, Geneva, Switzerland

Susanna Carboni

AMAL Therapeutics, Geneva, Switzerland

Wilma Besson-Di Berardino

AMAL Therapeutics, Geneva, Switzerland

Erika Riva

AMAL Therapeutics, Geneva, Switzerland

Marie-Laure Santiago-Raber

AMAL Therapeutics, Geneva, Switzerland

Madiha Derouazi

AMAL Therapeutics, Geneva, Switzerland